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Abstract
The Plasmodium falciparum parasite’s ability to adapt to environmental pressures, such as the human immune system and
antimalarial drugs, makes malaria an enduring burden to public health. Understanding the genetic basis of these
adaptations is critical to intervening successfully against malaria. To that end, we created a high-density genotyping array
that assays over 17,000 single nucleotide polymorphisms (,1 SNP/kb), and applied it to 57 culture-adapted parasites from
three continents. We characterized genome-wide genetic diversity within and between populations and identified
numerous loci with signals of natural selection, suggesting their role in recent adaptation. In addition, we performed a
genome-wide association study (GWAS), searching for loci correlated with resistance to thirteen antimalarials; we detected
both known and novel resistance loci, including a new halofantrine resistance locus, PF10_0355. Through functional testing
we demonstrated that PF10_0355 overexpression decreases sensitivity to halofantrine, mefloquine, and lumefantrine, but
not to structurally unrelated antimalarials, and that increased gene copy number mediates resistance. Our GWAS and
follow-on functional validation demonstrate the potential of genome-wide studies to elucidate functionally important loci
in the malaria parasite genome.
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Introduction
Plasmodium falciparum malaria is a major public health challenge
that contributes significantly to global morbidity and mortality.
Efforts to control and eliminate malaria combine antimalarial
drugs, bed nets and indoor residual spraying, with vaccine
development a longer-term goal. Genetic variation in the parasite
population threatens to undermine these efforts, as the parasite
evolves rapidly to evade host immune systems, drugs and vaccines.
Studying genetic variation in parasite populations will expand our
understanding of basic parasite biology and its ability to adapt, and
will allow us to track parasites as they respond to intervention
efforts. Such understanding is increasingly important as countries
move towards reducing disease burden and the ultimate
elimination of malaria.
Given the potential impact of rapid evolution of P. falciparum in
response to control and eradication strategies, discovery and
characterization of P. falciparum genetic diversity has accelerated in
recent years. Since the first malaria genome was sequenced in
2002 [1], over 60,000 unique SNPs have been identified by
concerted sequencing efforts [2–4], and several genomic tiling
arrays [5–9] and low-density SNP arrays [10,11] have been
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developed to query this genetic variation. Recently the first
malaria GWAS was published [11], in which 189 drug-
phenotyped parasites from Asia, Africa and the Americas were
genotyped using a low-density array (3,257 SNPs); that study
identified loci under positive selection and found several novel
drug resistance candidates.
For our study, we adopted two strategies for identifying genes
involved in the malaria parasite’s adaptive response: searching for
signals of recent or ongoing natural selection, and searching for
loci associated with one important clinical adaptation—resistance
to antimalarial drugs. To make these searches possible, we began
by sequencing 9 geographically diverse strains of P. falciparum to
identify novel variation, thereby doubling the number of publicly
available SNPs to 111,536 (all accessible at plasmodb.org), and
used these SNPs to develop a high-density genotyping array
assaying 17,582 validated markers. After characterizing linkage
disequilibrium and population structure in our samples, we used
the arrays to search for evidence of both ongoing balancing
selection and recent positive selection, and to carry out a GWAS
that sought loci associated with resistance to thirteen antimalarial
agents. We then followed up one of the novel loci associated with
drug resistance in order to verify that variation there was
biologically involved in modulating drug response.
Results
Genetic Diversity
We identified global population structure among malaria
parasites using principal components analysis (PCA) of 57
genotyped culture-adapted parasite samples (Figure 1A, Table
S1, Figure S1). African, American and Asian samples form three
distinct clusters, reflecting the likely independent introduction of P.
falciparum from Africa into Asia and the Americas. There was little
evidence for structure within Africa, suggesting high gene flow
throughout the region (Figure S1). Asian and American parasites
however both show substantial internal structure.
There are also dramatic differences in linkage disequilibrium
(LD) between populations, with substantial LD extending less than
1 kb in Senegal, 10 kb in Thailand, and 100 kb in Brazil (Figure
S2). These observations are consistent with previous findings,
which showed that LD decays more rapidly in Africa, due either to
founder effects in other continents [12] or to elevated outcrossing
frequencies in Africa [12,13], where higher transmission intensity
leads to a greater likelihood of sexual outcrossing rather than
selfing within the mid-gut of vector mosquitoes.
The short LD in malaria, driven by high levels of recombina-
tion, means that a high density of markers is required to identify
candidate loci in association studies, since causal variants not on
the array can seldom be tagged by neighboring alleles (Table S2).
On the other hand, short LD can aid in fine-mapping candidate
associations and greatly accelerates the search for causal genes.
Short LD also aids in identifying genomic regions under recent
positive selection with recombination-based methods, since the
increased LD in selected regions should stand out against the
short-LD background.
Detecting Signals of Natural Selection
We expect that many parasite proteins that interact with the
host immune system will be under balancing selection, because
they will be under selective pressure to maintain high levels of
diversity. Indeed, previous studies have shown that regions of the
P. falciparum genome that are highly polymorphic and appear to be
under balancing selection encode antigens that are recognized by
the human immune system [4]. We examined evidence for
balancing selection in our data by searching for regions with high
nucleotide diversity (as measured by SNP p) and low population
divergence (as measured by FST) (Figure 1B). When we examined
the loci lying in this region of the graph (Figure S3), we found a
number of known antigens and vaccine candidates. Loci in the
same region with unknown function are thus potential novel
antigens that trigger human immune response to malaria, and may
prove useful as biomarkers or as candidate vaccine molecules.
We carried out a similar search for loci under positive selection
by identifying regions with both low nucleotide diversity within
Senegal and Thailand and high population divergence between
the two populations (Figure 1B). We observed throughout the
genome that nucleotide diversity was lower for nonsynonymous
SNPs than for intergenic SNPs (Figure S4), a characteristic result
of widespread purifying selection. At the same time, nonsynon-
ymous SNPs exhibited significantly greater divergence than
intergenic SNPs in all pairwise population comparisons, suggesting
the effect of positive selection in local P. falciparum populations.
Nonsynonymous SNPs with low diversity within a population and
high divergence between the two populations studied may
represent polymorphisms responsible for adaptive evolution.
We also carried out a genome-wide scan for recent positive
selection using the long-range haplotype (LRH) test [14], which
identifies common variants that have recently spread to high
prevalence using recombination as a clock. Approximately 15
genes were identified as having undergone recent positive selection
by this approach, including known drug resistance loci (pfcrt and
dhfr) as well as multiple members of the acyl-CoA synthetase (ACS)
and ubiquitin protein ligase families (Figures S5 and S6); these
latter genes also exhibit high divergence between Senegal and
Thailand (Figure 1B), evidence for selection that is recent and
population-specific. Taken as a group, the genes identified by the
LRH test show a significant enrichment for higher than average
population divergence (as measured by FST, Mann-Whitney
U=1583, P= 0.0071). All of these loci (Table S3, Dataset S1),
which include genes in the folate metabolism, lipid biosynthesis
Author Summary
Malaria infection with the human pathogen Plasmodium
falciparum results in almost a million deaths each year,
mostly in African children. Efforts to eliminate malaria are
underway, but the parasite is adept at eluding both the
human immune response and antimalarial treatments.
Thus, it is important to understand how the parasite
becomes resistant to drugs and to develop strategies to
overcome resistance mechanisms. Toward this end, we
used population genetic strategies to identify genetic loci
that contribute to parasite adaptation and to identify
candidate genes involved in drug resistance. We examined
over 17,000 genetic variants across the parasite genome in
over 50 strains in which we also measured responses to
many known antimalarial compounds. We found a number
of genetic loci showing signs of recent natural selection
and a number of loci potentially involved in modulating
the parasite’s response to drugs. We further demonstrated
that one of the novel candidate genes (PF10_0355)
modulates resistance to the antimalarial compounds
halofantrine, mefloquine, and lumefantrine. Overall, this
study confirms that we can use genome-wide approaches
to identify clinically relevant genes and demonstrates
through functional testing that at least one of these
candidate genes is indeed involved in antimalarial drug
resistance.
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and ubiquitin pathways, should be viewed as candidates for
functional follow-up and further characterization.
Genome-Wide Associations with Drug Resistance
In order to directly assess the genetic basis for one important
response to antimalarial intervention, we carried out a GWAS to
identify loci associated with drug resistance in parasites. This same
approach can potentially be applied to many other clinically
relevant malaria phenotypes, e.g. host response, invasion, and
gametocyte formation. Our first step was to measure drug
resistance (IC50 values) to 13 antimalarial drugs (amodiaquine,
artemether, artesunate, artemisinin, atovaquone, chloroquine,
dihydroartemisinin, halofuginone, halofantrine, lumefantrine,
mefloquine, piperaquine and quinine) in 50 culture-adapted
parasites using a high-throughput assay (Tables S4 and S5, Text
S1, Dataset S1).
We performed the genome-wide association analysis using two
statistical tests: efficient mixed-model association (EMMA) and a
haplotype likelihood ratio (HLR) test (Figures S7, S8, S9, S10,
Methods). EMMA identifies quantitative trait associations in
individuals with complex population structure and hidden
relatedness; it has previously been shown to outperform both
PCA-based and lGC-based correction approaches in highly inbred
and structured mouse, maize, and Arabidopsis populations [15].
EMMA is particularly applicable for small and structured sample
sets: one of its first applications was in a study of 24 diploid mouse
strains [15], essentially the same sample size as in our study (50
haploid strains). The HLR test is a multi-marker test designed to
detect the association of a single haplotype with a phenotype, and
is particularly powerful when the associated haplotype experienced
recent strong selection (and is therefore long) and occurs on a low-
LD background [16]; it is therefore particularly appropriate for
this study. We addressed the effect of population structure in the
HLR test using population-specific permutation (Methods). When
used together, these two complementary approaches provide a
highly sensitive screen for association signals within the P.
falciparum genome.
The well-characterized chloroquine resistance locus, pfcrt, served
as a positive control for our GWAS methods (Figure 2A and 2C,
Table S2), an important test given our small sample size and the
limited LD present in P. falciparum. As expected, we found evidence
for association with resistance to chloroquine using both tests,
Figure 1. Parasite global population structure and genetic diversity versus divergence. (A) Population structure is visualized using the
first two principal components of genetic variation for 57 parasites. Solid circles represent individual parasites, with colors assigned by reported
origin: Africa in red, America in blue, and Asia in green. The nine strains used for ascertainment sequencing are indicated with (*). (B) Genetic diversity
(SNP p) in Senegal versus divergence (FST) between Senegal and Thailand is reported for 688 genes containing.3 successfully genotyped SNPs. Blue
diamonds: enzymes, acyl-CoA synthetases (ACS) or transporters; red diamonds: antigens, vars, rifins, stevors or surfins; gray diamonds: all other genes.
Gene IDs (PlasmoDB.org) for highlighted genes are listed in Table S7. A gene with unknown function is flagged with (*) to indicate that SNP p is off-
scale (0.014).
doi:10.1371/journal.pgen.1001383.g001
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consistent with previous studies [11]; EMMA yielded evidence for
association with genome-wide signficance, while the signal from
the HLR test fell just short of genome-wide significance
(Figure 2C).
Applying the same tests to the other drug phenotypes, we
detected numerous novel loci showing significant associations with
drug resistance (Figure 2A and 2D, Table 1). Quantile-quantile
plots for each test demonstrate that we were able to effectively
control for population structure (Figure 2B). Despite our small
sample size and the low LD in P. falciparum, in total eleven loci
achieved genome-wide significance for association with resistance
to five different drugs: amodiaquine, artemisinin, atovaquone,
chloroquine and halofantrine. In most cases, the short extent of
LD allowed localization to individual genes. Among the loci
identified were various transporters and membrane proteins, as
well as five conserved genes with unknown function (Table 1,
Dataset S1).
Functional Validation of a Novel Resistance Candidate
Demonstrating that a signal of association actually reflects a
causal molecular process requires functional testing and validation
of the candidate locus, both because of concerns about power and
reproducibility of genetic association tests, and because even a
robust statistical correlation need not imply biological causation.
To confirm the ability of GWAS to identify functionally relevant
candidates, we investigated one of our association findings,
PF10_0355, in greater depth. This gene contains multiple SNPs
associated with halofantrine resistance (Figure 2D), and encodes a
putative erythrocyte membrane protein (PlasmoDB.org) charac-
terized by high genetic diversity.
We set out to determine the role of PF10_0355 in halofantrine
resistance by transfecting halofantrine-sensitive Dd2 parasites with
episomal plasmids containing the PF10_0355 gene from a
halofantrine-resistant parasite (SenP08.04), a technique that is
used routinely for stable transgene expression [17]. Two
independent transfectants overexpressing the PF10_0355 gene
from SenP08.04 both showed reduced susceptibility to halofan-
trine when compared with the Dd2 parent or a transfection
control (Figure 3A), suggesting that this gene is indeed involved in
modulating parasite drug response.
Two independent transfectants overexpressing the endogenous
PF10_0355 gene from halofantrine-sensitive Dd2 also showed
reduced susceptibility to halofantrine (Figure 3A), however,
pointing to a role of overexpression in the observed resistance.
Because PF10_0355 is annotated as a putative erythrocyte
membrane protein and belongs to the merozoite surface protein
3/6 family, we tested the hypothesis that the observed effect was
the by-product of a growth or invasion-related process, rather than
resistance due to a direct interaction with the antimalarial itself.
To that end, we expanded our drug testing in the transfectant lines
to include other antimalarials, some structurally related and some
unrelated to halofantrine.
Figure 2. Genome-wide association study (GWAS) results. (A) Genome-wide significant associations were found for five antimalarials (out of
thirteen tested) using EMMA and HLR tests. They include pfcrt (chromosome 7) associated with chloroquine resistance and eleven novel associations
with resistance to several drugs, listed in Table 1. (B) Quantile-quantile plots for the P-value distributions in (A) show no significant confounding from
population structure. Bonferroni-corrected genome-wide significance is marked with a dashed line; Benjamini-Hochberg significance is marked with a
dotted line. (C-D) Close-ups are shown of the GWAS signal (top) and haplotypes (bottom) for resistance to (C) chloroquine (CQ) around the gene pfcrt
and (D) halofantrine (HFN) around the gene PF10_0355. Yellow: sensitive allele; red: resistant allele; Blue: no data. Isolates are ordered by IC50, with the
highest IC50 on the bottom.
doi:10.1371/journal.pgen.1001383.g002
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Overexpression of PF10_0355 from either the Dd2 or the
SenP08.04 parent caused increased resistance to the structurally
related antimalarials mefloquine and lumefantrine (Figure 3B and
3C), but had no effect on parasite susceptibility to the structurally
unrelated antimalarials chloroquine, artemisinin or atovaquone
(Figure 3D and 3E). Indeed, we found evidence of cross-resistance
between halofantrine and both mefloquine and lumefantrine
(Figure 4). We also observed cross-resistance between halofantrine
and artemisinin, which is expected as cross-resistance between
aminoquinolines and artemisinin compounds has been previously
demonstrated [11,18] and resistance to all these drugs has been
shown to be mediated by changes in pfmdr1 copy number [19,20].
Overexpression of PF10_0355, however, alters parasite suscepti-
bility to the aminoquinolines but not to artemisinin, suggesting
Table 1. Eleven genome-wide significant associations with antimalarial drug resistance.
chr SNPs test drug P-value genes PlasmoDB description
6 674,154 EMMA ATV 2.36E207 PFF0785w Ndc80 homologue, putative
7 459,787 EMMA CQ 4.72E207 MAL7P1_27 chloroquine resistance transporter
10 1,435,226, 1,435,286,
1,435,370, 1,437,695,
1,437,718, 1,441,590,
1,444,868
HLR_risk_6
(2 overlapping hits)
HFN 4.71E206,
4.25E206
PF10_0355,
PF10_0356
erythrocyte membrane protein putative, liver stage
antigen 1
11 657,349 EMMA ATV 4.01E206 PF11_0178 conserved unknown
11 738,407 EMMA HFN 7.20E207 PF11_0203 peptidase, putative
11 1,123,028, 1,124,030 HLR_risk_2 ADQ 5.26E206 PF11_0302 conserved unknown
12 1,964,935 EMMA HFN 6.15E208 PFL2285c conserved unknown
13 757,689 EMMA HFN 1.28E207 PF13_0101 conserved unknown
14 1,233,470 EMMA HFN 5.32E207 PF14_0293 conserved unknown
14 2,814,793,
2,815,714
HLR_risk_2 ARTS 4.90E206 PF14_0654 aminophospholipid transporter, putative
14 3,130,449 EMMA ATV 1.03E206 PF14_0729 early transcribed membrane protein 14.2
Positions are given with respect to the PlasmoDB 5.0 reference assembly of 3D7. Drug abbreviations are ATV: atovaquone; CQ: chloroquine; HFN: halofantrine; ADQ:
amodiaquine; ARTS: artemisinin. The HLR test for CQ-pfcrt association is just below the genome-wide significance threshold and is omitted here, but is shown in
Figure 2C.
doi:10.1371/journal.pgen.1001383.t001
Figure 3. Overexpression of PF10_0355 decreases parasite susceptibility to halofantrine (HFN) and related antimalarials. Parasite
susceptibility to six antimalarials was measured by 3H-hypoxanthine incorporation. Comparisons were made between Dd2 (HFN-sensitive strain) and
SenP08.04 (HFN-resistant strain), as well as 4 transfected lines. ‘‘Dd2+Dd2’’: Dd2 parasites overexpressing PF10_0355 from Dd2; ‘‘Dd2+P08’’: Dd2
parasites overexpressing PF10_0355 from SenP08.04. Overexpression of PF10_0355 decreases parasite susceptibility to (A) HFN and structurally
related (B) mefloquine (MFQ) and (C) lumefantrine (LUM). Overexpression of PF10_0355 does not alter parasite susceptibility to (D) chloroquine (CQ),
(E) artemisinin (ARTS) or (F) atovaquone (ATV). Mean IC50 6 standard error is shown. Significance levels: *: p,0.05, **: p,0.01, ***: p,0.001.
doi:10.1371/journal.pgen.1001383.g003
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that this effect is specific for that set of structurally related
compounds and distinct from the effect of pfmdr1, which seems to
exert a global effect of resistance to unrelated compounds (i.e. both
aminoquinolines and artemisinins). Using the Dd2 parasite line,
which has amplified pfmdr1 copy number, as a background for
PF10_0355 overexpression allowed us to distinguish between
cross-resistance to a structurally related class of compounds
(mediated by PF10_0355 overexpression) and pan-resistance to
multiple classes of drugs.
Given that overexpression of the PF10_0355 gene both from a
halofantrine-resistant and from a sensitive parasite conferred
resistance to halofantrine-related drugs, we investigated whether
gene amplification might be driving the observed resistance, as it
often does for antimalarial drugs [21–26]. We quantified
PF10_0355 copy number in our transfectants and found that the
transfectant with the highest IC50 for all three drugs (Dd2+P08B)
also had the highest PF10_0355 copy number, as measured by
quantitative PCR (qPCR) (Figure 5A). Furthermore, when we
examined the PF10_0355 gene on our SNP array, we detected a
substantial increase in hybridization intensity at the PF10_0355
locus compared to the genome average, suggesting that this gene is
amplified in some parasites (Figure 5B). The amplified region
appears only to contain the PF10_0355 gene itself and not
surrounding loci. We observed a similar pattern at pfmdr1 on
chromosome 5, where copy number variation is well established
(Figure S11). Follow-up qPCR analysis of 38 parasite lines
confirmed that parasites with amplified PF10_0355 have a greater
mean halofantrine IC50. (Figure 5C, Table S6, Dataset S1). Copy
number variation was further confirmed in a number of parasites
by quantitative Southern blotting (Figure S12).
Figure 4. Correlations between antimalarial drugs tested. (A) Pearson correlation values (r) between log10(IC50) values are rendered as a color
in a symmetric correlation matrix (red: correlated; white-uncorrelated, blue: inversely correlated). Thirteen antimalarials are measured: artemether
(ARTM), artesunate (ARTN), artemisinin (ARTS), dihydroartemisinin (DHA), halofantrine (HFN), lumefantrine (LUM), mefloquine (MFQ), quinine (QN),
chloroquine (CQ), amodiaquine (ADQ), atovaquone (ATV), piperaquine (PIP), and halofuginone (HFG). Drugs are grouped by structural relatedness.
(B–F) Correlation plots are given with a linear regression line for HFN compared to the 5 other drugs tested for antimalarial resistance with PF10_0355
overexpression: (B) LUM, (C) MFQ, (D) ATV, (E) CQ, and (F) ARTS.
doi:10.1371/journal.pgen.1001383.g004
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Figure 5. Copy number variation at PF10_0355 is associated with HFN resistance. (A) Mean PF10_0355 copy number (6 standard deviation
for three replicates) in the parent Dd2 and transfected lines from qPCR analysis. Dd2+Dd2: Dd2 parasites overexpressing PF10_0355 from HFN-
sensitive Dd2; Dd2+P08: Dd2 parasites overexpressing PF10_0355 from HFN-resistant SenP08.04. Copy number was compared to the reference locus
PF07_0076. (B) Increased hybridization intensity at PF10_0355 on the high-density SNP array, measured by Z-scores for normalized and background-
corrected data, for the HFN-resistant isolate SenP19.04. (C) Strains with increased copy number of PF10_0355 (as measured by qPCR.1.2x 3D7) show
a significantly higher resistance to HFN (p= 0.02, Student t-test).
doi:10.1371/journal.pgen.1001383.g005
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Discussion
In this study we used natural selection and genome-wide
association methods to probe the genetic basis of adaptation in P.
falciparum. These approaches are complementary: scanning for
selected loci permits an unbiased search for unknown adaptive
changes, but provides little information about the processes at
work, while GWAS gives a focused look at one easily identified
(and clinically critical) adaptive phenotype. Results from both
approaches open up new avenues for study, as we seek to
understand the biological significance of the findings.
The specifics of our strategy were designed to cope with two
potential limitations in applying genome-wide population genetic
approaches to malaria: small sample sizes, due to the difficulty in
adapting parasites to culture and assessing drug and other
phenotypes; and a lack of correlation (LD) between nearby
variants in the parasite genome, which limits our ability to infer
untyped SNPs from genotyped markers. The second limitation we
addressed by developing a high-density genotyping array (based on
new sequencing), to increase the fraction of genetic variation that
we could directly interrogate, while the effect of the first was
mitigated by the phenotype we targeted in our GWAS.
Drug resistance is a phenotype well-suited for GWAS because it
is expected to be caused by common alleles of large effect at few
genomic loci [27]. If this is the case, associations will be much
easier to detect than in a typical human GWAS, in which the
phenotype is caused by alleles at many loci that are either rare or
of small effect. Additionally, the haploid nature of the intra-
erythrocytic stage of P. falciparum further heightens GWAS power
by eliminating the issue of allelic dominance. Finally, the increased
LD caused by recent selection for drug resistance counteracts the
loss of power that comes from short LD, small sample size, and the
temporal and geographic stratification of the parasite population
that we examined. Thus, despite the potential limitations, we were
able to detect a known drug resistance locus (pfcrt), observed little
P-value inflation in our GWAS data (Figures S8, S9, S10), and
identified a number of genome-wide significant loci associated
with drug resistance. Part of this success was likely due to specific
tests we used to account for population structure.
Going beyond these statistical tests, we went on to functionally
validate one of these loci, demonstrating that increased PF10_0355
copy number confer resistance to three structurally related
antimalarial drugs. This demonstrates the feasibility of coupling
GWAS and functional testing in the malaria parasite for
identifying and validating novel drug resistance loci and illustrates
the power of GWAS to find functionally important alleles.
Comparing our results to the recent GWAS described by Mu, et
al. [11], which was also directed at finding drug-resistance loci, we
see that, beyond the well-known pfcrt locus, there was no overlap
between the associations identified by each study. Differing sets of
drugs tested and analytical methods explain much of the
disagreement. Of the eleven candidate associations in Table 1,
one (that with pfcrt) was found by both studies, eight were
associations with drugs not assayed in Mu, et al. (atovaquone and
halofantrine), and two were found only with a haplotype-based
test, an approach not used by Mu, et al. Our candidate locus at
PF10_0355, in fact, would not have been detectable in the Mu
study because it was identified only by the multi-marker HLR test,
because it involved an association with halofantrine, and because
the Mu, et al. genotyping array lacked markers within 4 kb of the
gene (plasmoDB.org).
Different parasite populations and marker sets probably explain
many of the dihydroartemisinin, mefloquine and quinine associ-
ations identified by Mu, et al. but not seen in our data set. The
studies used different parasite population sets—theirs was
weighted toward southeast Asian strains, and ours toward African
strains—and selection pressures and selected alleles can both vary
between populations. Our smaller sample size also means that we
might lack power to identify some associations accessible to Mu, et
al. These difficulties are reflected in human GWAS studies as well,
where the ability to replicate associations using multiple tests and
in different sample sets has also been challenging to achieve [28].
Ultimately, the disparities in loci identified point to the role of
population analysis as a tool for candidate gene discovery and not
as a definitive study. Even within each study, there is little overlap
between the signals observed with different methods—our study
detects only one gene (pfcrt) by both GWAS tests (EMMA and
HLR), while Mu, et al. detected only two genes (unknowns, not
pfcrt) by both of their GWAS tests (Eigensoft and PLINK). Even a
well-designed GWAS serves only as a hypothesis-generating
experiment, and it is vital to empirically validate candidate loci
associated with a phenotype of interest. Especially given the small
sample sizes and relatively sparse marker density used in both
malaria GWAS studies to date, functional validation of candidates
is necessary to address concerns about false positive results.
Our functional result, that increased PF10_0355 copy number
confers decreased susceptibility to halofantrine, mefloquine and
lumefantrine, raises additional questions for study. Further work
will be needed to determine the precise contributions of copy
number variation and gene mutation to the parasite’s response to
these drugs. The biological function of this gene’s product is
unknown, but previous work indicates putative localization to the
parasite surface [29], as well as it being a potential target of host
immunity and balancing selection [30]. While the protein itself
does not appear to be a transporter, it is possible that it directly
binds drug or perhaps couples with transport proteins to modulate
drug susceptibility; interaction between membrane transporters
and non-channel proteins has been demonstrated in cancer, plant
and yeast systems [31–33]. Additional experiments are certainly
required to determine the precise role of PF10_0355 in
modulating parasite response to this class of compounds, including
assessing its relevance to resistance in natural populations, but it is
clear that alteration of this locus can mediate drug resistance in P.
falciparum.
Although halofantrine, mefloquine and lumefantrine are not
commonly used as primary interventions, widespread halofantrine
use has recently been documented in West Africa. Notably,
halofantrine was used to treat nearly 18 million patients between
1988 and 2005 [34,35], and it remains in production and use
today. Use of halofantrine, mefloquine or lumefantrine as
monotherapy may further explain how mutations and copy
number variation in the PF10_0355 gene were selected.
Lumefantrine is also currently used as a partner drug in the
artemisinin-based combination therapy (ACT) Coartem. The
shorter half-life of artemether allows lumefantrine to be present
as monotherapy, making it vulnerable to selection of drug resistant
mutants. As genetic loci associated with drug responses are
identified and validated, these provide new molecular biomarkers
to evaluate drug use and response in malaria endemic settings.
Thus, our findings have implications for defining molecular
biomarkers for monitoring partner drug responses as intervention
strategies, such as ACTs, are applied.
Beyond identifying a novel drug resistance locus, this study
illustrates the general utility of a GWAS approach for the
discovery of gene function in P. falciparum. Even with a small
and geographically heterogeneous sample of parasites, we
identified a number of new loci associated with drug response
and validated one of them. Larger samples from a single
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population will have much greater power to detect additional loci,
including those where multiple and low frequency alleles
contribute to resistance. Future GWAS have the potential both
to provide greater insights into basic parasite biology and to
identify biomarkers for drug resistance and other clinically relevant
phenotypes like acquired protection, pathogenesis, and placental
malaria.
Future GWAS will be able to counteract the loss of power
caused by low LD, either by focusing on parasite populations with
reduced outcrossing rates, or by studying cases of very strong
selective pressure. This issue will soon become moot, however, as
the declining cost of whole-genome sequencing makes it practical
to assay every nucleotide in the genome on a routine basis.
Culture-adapted parasites are amenable to robust and reproduc-
ible phenotypic characterization, but their limitations—the
potential for artifactual mutations during adaptation and for a
biased selection of clones within a given infection—mean that
genetic changes identified using them require both functional
validation and demonstration that the changes are important
during natural infection. As direct sequencing of clinical isolates
with demonstrable clinical phenotypes such as ex vivo drug response
or invasion properties becomes increasingly feasible, sequencing
will enable us to directly identify genetic changes in the parasite
associated with clinically relevant phenotypes. In the years ahead,
genome analysis of P. falciparum has the potential to identify genetic
loci associated with many phenotypes, enhance our understanding
of the biology of this important human pathogen, and inform the
development of diagnostic and surveillance tools for malaria
eradication.
Methods
Parasites, Drug Testing, and DNA Isolation
Parasite samples and origins are detailed in Text S1 and Table
S1. Parasites were maintained by standard methods [36] and were
tested for their response to amodiaquine, artemether, artesunate,
artemisinin, atovaquone, chloroquine, dihydroartemisinin, halo-
fuginone, halofantrine, lumefantrine, mefloquine, piperaquine and
quinine according to the methods outlined by Baniecki, et al. [37]
(Table S4, Figure S13, Text S1). Follow-up drug testing was done
by measuring uptake of 3H-hypoxanthine [38]. Nucleic acids were
obtained from parasite cultures using Qiagen genomic-tips
(Qiagen, USA). All DNA samples were evaluated by molecular
barcode [39].
Array Genotyping
We sequenced nine geographically diverse parasite isolates to
1.25x coverage, nearly doubling the number of publicly available
SNPs to 111,536 (Text S1). These parasites had been previously
sequenced to 0.25x coverage [2] and the deeper sequencing
allowed for more thorough SNP discovery. Using this combined
marker set, we created a high-density Affymetrix-based SNP array
for P. falciparum containing 74,656 markers. Arrays were
hybridized to 57 independent parasite samples (Table S1),
including 17 previously sequenced strains used as a validation
set. Genotype calls were produced using the BRLMM-P algorithm
[40]. Markers that did not demonstrate perfect concordance
between sequence and array data for the 17 strains were removed
(Text S1). The remaining 17,582 SNPs constituted the high-
confidence marker set used throughout this study (median marker
spacing 444 bp, mean spacing 1,316 bp). All genomic positions
and translation consequences are listed with respect to the
PlasmoDB 5.0 assembly and annotation. SNP genotype data are
publicly available on plasmodb.org (release 6.0, July 2009) and
dbSNP (Build B134, May 2011), accessible by searching for
submission batches Pf_0002 (sequencing of nine isolates) and
Pf_0003 (genotyping of 57 isolates) from submitter BROAD-
GENOMEBIO. Genotype data is also available as Dataset S2.
Principal Component Analyses
Principal components analysis (PCA) was performed using the
program SmartPCA [41]. All single-infection samples were used
for the analysis in Figure 1. Samples that tightly clustered with the
wrong continental population (A4, Malayan Camp and T2_C6)
represented likely cases of contamination and were thus omitted
from all other analyses.
Diversity/Divergence Analysis
We measured diversity using a statistic we term ‘SNP p,’ which
quantifies the average number of pair-wise differences among
samples from a given population at assayed SNPs. Population
divergence was measured using FST, calculated using the method of
Hudson, et al. [42]. Statistical evaluation of the significance of
differences in SNP p and FST among populations was performed
using a bootstrapping approach, where the SNP set was re-sampled
with replacement and each statistic recomputed 1000 times.
Linkage Disequilibrium (LD) Analysis
The statistic r2 was calculated within each population for all
pairs of SNPs sharing the same chromosome [43]; pairs were
binned by distance and averaged within each bin. The level of LD
between unlinked markers was estimated by calculating r2 between
all pairs of SNPs on different chromosomes. To determine the bias
caused by small sample size, the unlinked calculation was
repeated, with the change that for each pair of SNPs, the
genotype for one was taken from one strain while the genotype for
the second was taken from another strain. This background value
of r2 was calculated separately for the possible pairs of different
strains and then averaged. Only single infections, as assessed by
molecular barcode, were used.
Long Range Haplotype (LRH) Analysis
Because of the small number of samples, LRH results for
individual continental populations had a high level of variance.
Thus, we pooled together samples from Africa (n = 26) and Asia
(n = 18, excluding India), as suggested by our PCA analysis. SNPs
included in the analysis had a minor allele frequency of at least
0.05 and a call rate of at least 0.8; missing genotypes were imputed
using PHASE. LRH analysis was performed using Sweep. Each
SNP defined two core alleles, one base pair in length. We
calculated relative extended haplotype homozygosity (REHH) for
each core allele, to its left and right [44], yielding up to four
REHH scores per SNP locus. We standardized the REHH scores
as a function of core allele frequency, defined on a discrete grid
from 0.05 to 0.95 with even spaces of 0.025. This yielded a
normally-distributed set of Z-scores for which we calculated
corresponding P-values and Q-values.
Genome-Wide Association Study (GWAS)
We performed a GWAS for drug resistance to thirteen
antimalarials across 50 of our genotyped samples. 7,437 SNPs
that had a minor allele count of five samples as well as an 80% call
rate under every phenotype condition were used for GWAS. A
Bonferroni significance threshold of –log10(P-value) .5.17 was
used for all tests. See Text S1 for more details on GWAS methods.
The Efficient Mixed-Model Association (EMMA) test [15]
models quantitative trait associations to a data set with complex
PF10_0355 Changes Confer Antimalarial Resistance
PLoS Genetics | www.plosgenetics.org 9 April 2011 | Volume 7 | Issue 4 | e1001383
population structure and hidden relatedness. It calculates a
genotype similarity matrix instead of discrete categories and does
not require a priori specification of populations. The resulting P-
value distributions demonstrate little remaining effect from
population structure (Figure S8) while retaining power to find a
number of associations at genome-wide significance (Figure S8,
Figure 2A, Table 1).
The Haplotype Likelihood Ratio (HLR) test [16] models the
likelihood that a single, resistant haplotype rose to dominance
while all other haplotypes proportionally decreased. PLINK [45] is
used to produce sliding window haplotypes across the genome and
calculate haplotype frequencies for input to the HLR test. We
produced input for all 2-, 4- and 6-marker windows. The LOD
scores generated by the HLR test were converted to empirical
pointwise P-values by performing approximately 370,000 permu-
tations of the null model for each test condition, allowing us to
calculate empirical P-values up to a significance of 1025.6. We
preserved population-specific phenotype frequencies by permuting
only within each of three populations defined by our PCA analysis
(Table S1). Resulting P-value distributions fit expectations well for
the vast majority of test conditions (Figures S9, S10) and the test
demonstrates power to detect a number of loci at genome-wide
significance (Figure 2A, Table 1).
Copy Number Variation (CNV)
Copy number was assessed by evaluating the hybridization
intensity at the PF10_0355 locus on the high-density SNP array
(Text S1). Follow-up analyses were done by quantitative real-time
PCR (qPCR) of the PF10_0355 locus using the Delta Delta Ct
method [46]. PF10_0355 was compared to the reference locus
PF07_0076 and 3D7 was used as a reference strain. A summary of
PF10_0355 copy number for all parasite strains tested is provided
in Table S6. Select resistant strains that were found to have
multiple copies of PF10_0355 were further analyzed by quanti-
tative Southern blotting and PF10_0355 copy number was
compared to the dhps gene from the 3D7 strain [47].
PF10_0355 Overexpression
The full length ORF of PF10_0355 was amplified from either
the Dd2 (HFN sensitive) or SenP08.04 (HFN resistant) parasite
isolate and cloned into the pBIC009 plasmid under the expression
of the Hsp86 promoter. Plasmid DNA was isolated, tranfected into
the Dd2 parasite strain and stable transfectants were selected with
2.5 nM WR99210 [48]. Parasites from two independent experi-
ments for each vector type (Dd2+Dd2 and Dd2+SenP08.04) were
isolated and successful transfection was confirmed by plasmid
rescue as well as episome-specific PCR and sequencing. Addition-
ally, a vector control strain was made by transfecting Dd2 parasites
with the pBIC009 plasmid containing the firefly luciferase gene
(EC 1.13.12.7).
Supporting Information
Dataset S1 Drug data, PF10_0355 copy number data, and top
GWAS and LRH hits.
Found at: doi:10.1371/journal.pgen.1001383.s001 (0.06 MB
XLS)
Dataset S2 Genotype data. Tab separated text file containing
genotype data for 57 isolates across 17,582 SNPs. Additional
information such as translation consequences (based on PlasmoDB
v5.0 annotations) are also provided.
Found at: doi:10.1371/journal.pgen.1001383.s002 (3.29 MB
TXT)
Figure S1 Principal components analysis of population structure
within A) Africa B) the Americas, and C) Asia. Plots of the first two
principal components using Eigenstrat [16] using the Affymetrix
array. Each solid circle represents an individual, and the color is
assigned according to the reported origin.
Found at: doi:10.1371/journal.pgen.1001383.s003 (0.56 MB
DOC)
Figure S2 Linkage disequilibrium (LD), measured by r2, for
each of the three population samples (Senegal, Thailand, Brazil).
Plotted are r2 for linked markers (red lines) and for unlinked
markers (blue lines), as well as the level of background LD
expected because of small sample size (green lines).
Found at: doi:10.1371/journal.pgen.1001383.s004 (0.06 MB
DOC)
Figure S3 Genes were classified by gene ontology (GO)
functional categories and stratified by level of nucleotide diversity
(p) as estimated by Z-scores. Select categories (highest five and
lowest five categories along with categories in between that differ
by incremental Z-scores) are shown. The majority of genes in GO
categories for molecules found at the cell membrane have high
levels of nucleotide diversity, while most of the genes classified into
GO categories for conserved molecules lack nucleotide diversity.
Found at: doi:10.1371/journal.pgen.1001383.s005 (0.51 MB
DOC)
Figure S4 SNP diversity and divergence by translation conse-
quence. Diversity at assayed SNPs (SNP p) and Divergence
between different populations as assayed by FST, for different
classes of SNPs: intergenic (4,263 SNPs), intronic (584 SNPs),
synonymous (3,957 SNPs), and nonsynonymous (8,778 SNPs).
Intronic SNPs have the widest error bars due to their relative
sparseness on the array. Non-synonymous SNPs are generally
among the least diverse and most differentiated class of SNPs.
Found at: doi:10.1371/journal.pgen.1001383.s006 (1.58 MB EPS)
Figure S5 Relative extended haplotype homozygosity (REHH)
scores. Relative extended haplotype homozygosity (REHH) scores
prior to any normalization, plotted for each core allele, (A) indexed
by chromosome and position, and colored by chromosome, and
(B) as a function of core allele frequency.
Found at: doi:10.1371/journal.pgen.1001383.s007 (0.61 MB
DOC)
Figure S6 Long-range haplotype (LRH) analysis yields genome-
wide significant candidates for recent positive selection. For each
core allele, we calculated relative extended haplotype homozygos-
ity (REHH), and from the set of all REHH scores we calculated a
corresponding distribution of Q-values. We plotted -log10(Q-value),
for all Q-values ,1, for each core allele, indexed by chromosome
and position, and colored by chromosome. The red dotted line
corresponds to the typical Q-value significance threshold of 0.05.
Gene annotations from PlasmoDB.org for some significant scores
are labeled. For comparison, the well-known sweeps around drug
resistance loci pfcrt and dhfr are labeled. This data is also shown in
tabular form in Table S3.
Found at: doi:10.1371/journal.pgen.1001383.s008 (0.23 MB TIF)
Figure S7 GWAS P-value distributions for Fisher’s exact test,
permuted Fisher’s exact test, and Cochran-Mantel-Haenszel
(CMH) tests. Quantile-quantile plots (qq-plots) show log P-values
for every SNP on the y axis against the null expectation on the x
axis. Fisher’s exact test results generally show P-value inflation due
to confounding effects from population structure for many drugs
("Fish"). As such, no results from this test are reported. To account
for population structure, permutations of the null distribution were
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performed while preserving phenotypic associations to three
predefined population clusters ("Fishp"). CMH also performs a
stratified association test given predefined population clusters
("CMH"). The permuted Fisher’s test and CMH test results show
appropriate correction for population structure, but show no hits
at genome-wide significance to report.
Found at: doi:10.1371/journal.pgen.1001383.s009 (0.47 MB TIF)
Figure S8 GWAS results for the Efficient Mixed-Model Associ-
ation (EMMA) test. QQ-plots show little to no confounding effect
from population structure, with the possible exception of artesunate
(ARTN). The significant ARTN result is not reported in Table 1 or
Figure 2 for this reason. Manhattan plots depict the genomic
location of significant hits, also reported in Table 1 and Figure 2.
Found at: doi:10.1371/journal.pgen.1001383.s010 (0.61 MB TIF)
Figure S9 GWAS P-value distributions for the Haplotype
Likelihood Ratio (HLR) tests for association for drug resistance.
Population-sensitive permutations of the null model were used to
calculate P-values from LOD scores. Final distributions of P-values
show little to no confounding effect from population structure for
most tests. Exceptions include the 6-SNP artemether (HLR_ris-
k_6_ARTM) test and the 4-SNP amodiaquine (HLR_ris-
k_4_ADQ) test--these results are not reported in Table 1 or
Figure 2. Manhattan plots for other tests that reached genome-
wide significance are in Figure 2A.
Found at: doi:10.1371/journal.pgen.1001383.s011 (3.52 MB TIF)
Figure S10 GWAS P-value distributions for Haplotype Likeli-
hood Ratio (HLR) tests for association for drug sensitivity.
Population-sensitive permutations of the null model were used to
calculate P-values from LOD scores. Final distributions of P-values
show little to no confounding effect from population structure.
Genome-wide significant hits include piperaquine (HLR_pro-
tect_4_PIP) on a haplotype that spans PF07_0126, PF07_0127
and MAL7P1_167 and amodiaquine (HLR_protect_4_ADQ) on a
haplotype in PFL1800w. A chloroquine hit on pfcrt just misses
genome-wide significance. These results are not reported in Table 1.
Found at: doi:10.1371/journal.pgen.1001383.s012 (3.51 MB TIF)
Figure S11 Intensity Z-score for the Affymetrix array across
chromosome 5. The results illustrate that probes for many of the
SNPs assayed within the pfmdr1 (888-988 k) locus exhibit notably
higher hybridization intensity values in Dd2 relative to the other
parasites, with 13 assays exhibiting average intensities greater than
2 standard deviations higher than observed in other strains. This is
consistent with the copy number variation reported in the pfmdr1
locus, with 3–4 copies present in the Dd2 strain relative to a
collection of other strains.
Found at: doi:10.1371/journal.pgen.1001383.s013 (0.35 MB
DOC)
Figure S12 PF10_0355 copy number variation measured by
Southern blotting. Select parasite isolates were digested with
AflIII, EcoRV and XbaI and fragments were detected using
probes to portions of the PF10_0355 and dhps genes. Primers used
for making probes were: dhps F: 59-GTG ATT GTG TGG ATC
AGA AGA TGA ATA ATC-39; R: 59-GGA TTA GGT ATA
ACA AAA GGA CCA GAG G-39; PF10_0355 F: 59-GGG GAA
AGC ATA TAA TAA TAC TAT AGA TGC-39; R: 59-CTT
GGA GGA ACA AGA ACC CCC TTA TTA TCA-39
Radioactivity was measured using a phosphorimager plate and
quantified using Quantity One software (version 4.6.5). Halofan-
trine (HFN) response is listed as sensitive (S) or resistant (R) for
each strain.
Found at: doi:10.1371/journal.pgen.1001383.s014 (0.07 MB
DOC)
Figure S13 Drug resistance phenotype classification for sweep
and GWAS analyses. IC50 data were collected for thirteen anti-
malarial drugs against all genotyped parasite lines. Quantitative
IC50s were converted into binary "sensitive" and "resistant"
phenotypes at the cutoffs shown (see also Table S4). These binary
phenotypes were only used for the Haplotype Likelihood Ratio
(HLR) test. Drug abbreviations: amodiaquine (ADQ), artemether
(ARTM), artesunate (ARTN), artemisinin (ARTS), atovaquone
(ATV), chloroquine (CQ), dihydroartemisinin (DHA), halofugi-
none (HFG), halofantrine (HFN), lumefantrine (LUM), mefloquine
(MFQ), piperaquine (PIP) and quinine (QN).
Found at: doi:10.1371/journal.pgen.1001383.s015 (1.44 MB EPS)
Table S1 63 parasites used in the study with the name (parasite),
geographic origin (region, country), source, and molecular barcode
[8], as well as which samples were included in SNP discovery
(SEQ), population characterization (POP), long-range haplotype
(LRH), and GWAS analyses. For GWAS, * indicates that the
sample was used, but not included in any population cluster for
stratified or permuted analyses. The human control sample and
the ancestral P. reichenowi sample were not used in any analyses
reported here.
Found at: doi:10.1371/journal.pgen.1001383.s016 (0.12 MB
DOC)
Table S2 Analysis of the ability of SNPs on the array to act as a
proxy for or. This ability is measured using the standard
correlation metric r2. In our data set, 28% of SNPs in the
Brazilian sample (which has the most LD) had a nearby SNP on
the array in strong LD (r2.0.5) with it, while in the Senegal
sample the proportion was only 16%. Most of the time, therefore,
we will only be able to detect association with markers that have
been directly typed. The exception is strong selective sweeps,
which affect many markers within a region.
Found at: doi:10.1371/journal.pgen.1001383.s017 (0.18 MB
DOC)
Table S3 Long Range Haplotype (LRH) hits. All REHH hits
with Q-value ,0.25.
Found at: doi:10.1371/journal.pgen.1001383.s018 (0.19 MB
DOC)
Table S4 IC50 drug resistance phenotype data (nM). ND: No
data.
Found at: doi:10.1371/journal.pgen.1001383.s019 (0.12 MB
DOC)
Table S5 Parasites used in the GWAS. Parasites used, indicating
their nucleotide and amino acid sequence for various positions
(indicated by number) in the dhfr, pfcrt, and pfmdr1 gene loci.
Found at: doi:10.1371/journal.pgen.1001383.s020 (0.24 MB
DOC)
Table S6 PF10_0355 copy number summary for 38 parasites
tested by qPCR using the Delta Delta Ct method. Copy number
(CN) was compared to the reference locus PF07_0076 and 3D7
was used as a reference strain. A cut-off of 1.4 was used to define
PF10_0355 copy number greater than 1; parasites with greater
than 1 copy of PF10_0355 are shaded. Parasites are ranked by
Halofantrine (HFN) IC50: HFN-sensitive parasites are indicated by
an S and HFN-resistant parasites are indicated by an R.
Found at: doi:10.1371/journal.pgen.1001383.s021 (0.08 MB
DOC)
Table S7 Annotation and GeneID Information for identified
genes in Figure 1B.
Found at: doi:10.1371/journal.pgen.1001383.s022 (0.05 MB
DOC)
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Text S1 Supplemental methods.
Found at: doi:10.1371/journal.pgen.1001383.s023 (1.29 MB PDF)
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